Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C3H7O6P.2Na |
| Molecular Weight | 216.0374 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].OCC(O)COP([O-])([O-])=O
InChI
InChIKey=GEKBIENFFVFKRG-UHFFFAOYSA-L
InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2
DescriptionCurator's Comment: description was created based on several sources, including:
DOI: 10.1042/bj0280143
DOI: 10.1042/bj0280152
http://www.wikidoc.org/index.php/Glycerol_3-phosphate
Curator's Comment: description was created based on several sources, including:
DOI: 10.1042/bj0280143
DOI: 10.1042/bj0280152
http://www.wikidoc.org/index.php/Glycerol_3-phosphate
Synthetic glycerophosphates have been known for many years and have been prepared in several ways. The acid may exist in two isomeric forms, alpha and beta. The L-a-acid is the naturally occurring form; the b-acid, present in hydrolyzates of lecithins from natural sources, arises from migration of the phosphoryl group from the a-carbon atom. Dehydrogenation of L-glycerol 3-phosphate produces Dihydroxyacetone phosphate and is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway.
Originator
Curator's Comment: alpha-glycerophosphoric acid has long been known as a component of the lecithins and cephalins and may in a sense be looked on as a monoglyceride, the situation is much more favorable. Because of its great stability it has been possible for several workers to separate it from various phosphatides and free it from its accompanying beta-isomer. http://www.jbc.org/content/128/2/491.short
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: 2819.0 Gene Symbol: GPD1 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | KABIVEN Approved UseIt is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Launch Date2014 |
Sample Use Guides
19 to 38 mL/kg/day. The maximum infusion rate is 2.6 mL/kg/hour. Recommended infusion period is 12 to 24 hours.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C802
Created by
admin on Fri Dec 15 15:07:06 GMT 2023 , Edited by admin on Fri Dec 15 15:07:06 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
G43E72677U
Created by
admin on Fri Dec 15 15:07:06 GMT 2023 , Edited by admin on Fri Dec 15 15:07:06 GMT 2023
|
PRIMARY | |||
|
14754
Created by
admin on Fri Dec 15 15:07:06 GMT 2023 , Edited by admin on Fri Dec 15 15:07:06 GMT 2023
|
PRIMARY | |||
|
1555-56-2
Created by
admin on Fri Dec 15 15:07:06 GMT 2023 , Edited by admin on Fri Dec 15 15:07:06 GMT 2023
|
PRIMARY | |||
|
C80657
Created by
admin on Fri Dec 15 15:07:06 GMT 2023 , Edited by admin on Fri Dec 15 15:07:06 GMT 2023
|
PRIMARY | |||
|
DTXSID801014666
Created by
admin on Fri Dec 15 15:07:06 GMT 2023 , Edited by admin on Fri Dec 15 15:07:06 GMT 2023
|
PRIMARY | |||
|
216-304-3
Created by
admin on Fri Dec 15 15:07:06 GMT 2023 , Edited by admin on Fri Dec 15 15:07:06 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
